Vireo Growth Inc. has announced its intention to acquire Bridgewell Agribusiness LLC, a supplier of organic and non-GMO food and agricultural products. This strategic cannabis industry acquisition, detailed in a press release reported by Cannabis Business Times on May 26, 2026, involves an estimated closing purchase price of US$10,262,333.
The transaction is structured to expand Vireo Growth’s presence in the agricultural supply chain, integrating Bridgewell’s operations which focus on sourcing and supplying organic and non-GMO commodities and food ingredients to manufacturers and processors. Bridgewell acts as an intermediary, connecting agricultural producers with food manufacturers and ensuring adherence to certification and regulatory standards.
Transaction Structure and Financial Details
The aggregate consideration for the Bridgewell transaction is based on a base purchase price of US$40 million. This figure is subject to adjustments, including the assumption of approximately US$30 million of Bridgewell’s outstanding indebtedness and certain other transaction expenses. After these adjustments, the estimated closing purchase price is US$10,262,333.
In exchange for Bridgewell’s membership interests, Vireo Growth will issue an unsecured, subordinated convertible note to the seller, BWAB Holdings LLC. This convertible note, equal to the closing purchase price, is set to automatically convert on or after the second anniversary of the closing date into an estimated 16,552,150 subordinate voting shares of Vireo. The deemed price for these consideration shares is US$0.62 per share, a price that will be subject to the policies of the Canadian Securities Exchange and based on the volume-weighted average trading price of Vireo’s subordinate voting shares for 20 consecutive trading days ending two trading days prior to the closing date.
Regulatory and Securities Considerations
The completion of this cannabis industry acquisition is contingent upon several conditions. These include the negotiation and execution of definitive transaction agreements acceptable to both parties, and the receipt of all necessary regulatory approvals, including, if applicable, the approval of the Canadian Securities Exchange.
The consideration shares involved in the transaction have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the Securities Act), or any U.S. state securities laws. Consequently, these shares will be classified as “restricted securities” under Rule 144 of the Securities Act, limiting their offer or sale in the United States unless pursuant to an effective registration statement or an applicable exemption from registration requirements.
In Canada, the convertible note and consideration shares will be distributed under exemptions from prospectus requirements of applicable Canadian securities laws. They will be subject to a hold period of four months and one day from the date of distribution, in accordance with National Instrument 45-102 – Resale of Securities and other relevant Canadian securities legislation. This framework ensures compliance with both Canadian and U.S. securities regulations for the issuance and resale of the shares.
Market Context for the Acquisition
As previously reported by Hemp Gazette, the landscape for publicly listed cannabis and hemp companies continues to evolve through mergers and acquisitions. The integration of a non-GMO and organic agricultural supplier like Bridgewell into Vireo Growth’s operations could represent a move towards vertical integration or diversification within the agricultural commodities market.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
